3 Sep

Why Walgreens Stock Underperformed CVS in August


Walgreens Boots Alliance (WBA) stock underperformed CVS Health (CVS) stock last month, with Walgreens falling 6% and CVS rising about 9%. Walgreens’s retail sales and margins continued to be pressured.

In its fiscal 2019 third quarter, Walgreens’s US retail sales fell 2.9%, while its retail sales fell 1.1%. Its international retail pharmacy sales fell 7.3%, dragged down by Boots UK. Furthermore, Walgreens’s bottom line has fallen in the last two quarters, impacted by reimbursement pressure in the pharmacy segment and lower retail sales. These persistent challenges are blocking its stock’s recovery.

In comparison, CVS stock has benefited from two back-to-back strong quarters. The company reported its second-quarter results on August 7. In this year’s first two quarters, CVS’s bottom line has grown robustly, exceeding analysts’ estimates by a wide margin despite reimbursement pressure.

Backed by its strong first-half performance, CVS raised its fiscal 2019 earnings outlook. The company’s strong sales, earnings, and guidance helped its stock recover.

As of August 30, CVS stock had fallen about 7% this year, while Walgreens stock had fallen about 25.1%. However, in the last three months, CVS stock has risen 16.3%, whereas Walgreens has risen by about 4%.

What their valuation indicates

Walgreens stock has a low valuation, trading at 8.5 times analysts’ fiscal 2020 EPS estimate of $6.01. However, this low valuation is justified. Analysts expect Walgreens’s EPS to stay pressured in the near term, and be flat or rise marginally YoY (year-over-year) in fiscal 2020. Walgreens’s low single-digit revenue growth and reimbursement pressure could hurt its bottom line.

Meanwhile, CVS stock trades on par with Walgreens, but offers better growth based on analysts’ estimates. Analysts expect CVS Health’s top line to grow robustly in the near term, driven by the company’s Aetna acquisition. They also expect the company’s bottom line to grow more than Walgreens’s. Analysts expect CVS Health’s bottom line to grow by a low-to-mid-single-digit percentage in 2020 despite a tough YoY comparison.

Analysts recommend “buy” for CVS stock

Of the 26 analysts covering CVS Health stock, most (16 analysts) suggest “buy,” and ten suggest “hold.” Their target price of $68.73 for CVS implies a 12.8% upside based on its August 30 closing price of $60.92.

As for Walgreens, two of the 23 analysts covering the stock suggest “buy,” 18 suggest “hold,” and three suggest “sell.” Their target price of $57.32 implies an approximate 12% upside based on its August 30 closing price of $51.19.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.